Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

NAOV Relative to the S&P 500

NAOV Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the NanoVibronix, Inc. (NASD:NAOV) seasonal charts above shows that a Buy Date of November 24 and a Sell Date of February 12 has resulted in a geometric average return of 4.52% above the benchmark rate of the S&P 500 Total Return Index over the past 9 years. This seasonal timeframe has shown positive results compared to the benchmark in 4 of those periods. This is a poor rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 9 years by an average of 54.97% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

A word of caution: Only 9 years of data is available for shares of NAOV, perhaps insufficient to create a seasonal profile that accurately gauges the seasonal tendencies influencing the investment. Ideally, while 20 years is preferred, at least 10 years of data is required to perform a seasonal analysis that is considered to be reliable for future seasonal periods.

NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low-frequency, low-intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients as well as through distributor agreements.

To download NAOV seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: NAOV